Enveric Biosciences, Inc. (ENVB)
- Previous Close
0.8495 - Open
0.8154 - Bid 0.5798 x 200
- Ask 1.0500 x 200
- Day's Range
0.8000 - 0.8500 - 52 Week Range
0.6490 - 6.9800 - Volume
721,161 - Avg. Volume
4,835,503 - Market Cap (intraday)
6.131M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-8.0900 - Earnings Date May 15, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 23, 2008
- 1y Target Est
8.00
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
www.enveric.comRecent News: ENVB
Performance Overview: ENVB
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENVB
Valuation Measures
Market Cap
6.13M
Enterprise Value
-940.46k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.13
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.20%
Return on Equity (ttm)
-197.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.46M
Diluted EPS (ttm)
-8.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
2.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.9M
Research Analysis: ENVB
Company Insights: ENVB
ENVB does not have Company Insights